Breathe Well Live Well
Condition: Hypereosinophilic Syndrome
Interventions: Drug: Mepolizumab 300 mg; Drug: Placebo matching mepolizumab; Drug: Active OCS capsules (5 mg prednisolone or prednisone); Drug: Placebo matching OCS capsules
Sponsor: GlaxoSmithKline
Not yet recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Hypereosinophilic syndrome secondary to strongyloides infection: a case of recurrent asthma exacerbations.
BMJ Case Rep. 2013;2013
Authors: Khan WA, Santhanakrishnan K
Abstract
Hypereosinophilic syndrome is a disease characterised by a persistently elevated eosinophil count. The syndrome can be reactive to infections, autoimmune disease, cancers, etc. Multiple organ involvement can occur including cardiomyopathies, pulmonary involvement and neuropathies. We describe a case of a patient who presented with signs and symptoms of asthma with recurrent asthma exacerbations, but in fact proved to be hypereosinophilic syndrome secondary to strongyloides infection.
PMID: 23964035 [PubMed – in process]
View full post on pubmed: asthma